Page 2 - Pendulum Glucose Control News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pendulum Therapeutics Raises $54 Million to Meet Surging Customer Demand Strong Loyalty Among Subscribers: After Five Months, 74% of Key Customer Segment Remain Active Users Company Created New Product Category, Filling Market Gap Between Supplements and Prescription Drugs News provided by Share this article SAN FRANCISCO, April 7, 2021 /PRNewswire/ --  Pendulum Therapeutics – a biotech company improving health through products targeting the microbiome – today announced a $54 million investment led by Meritech Capital with participation from existing investors including Sequoia Capital, ...

To embed, copy and paste the code into your website or blog: Welcome to our monthly roundup of regulatory and litigation highlights impacting the dietary supplement and personal care products industries.  Sit back, relax, and enjoy the read.  February was a short month, with a lot going on. NAD Health claim substantiation was front and center before NAD in a monitoring case involving Pendulum Therapeutics and a “medical probiotic” product featuring claims such as “The only medical probiotic clinically shown to lower A1C & blood glucose spikes for the dietary management of T2D*” (*Co...

NAD supports claims being made by ‘medical probiotic’ manufacturer ©Getty Images - Image_Jungle Probiotics manufacturer Pendulum Therapeutics Inc. got some welcome news today when the National Advertising Division announced that it has found that the claims the company makes for dietary control of Type 2 diabetes are supported by scientific evidence. The NAD ruling said that the scientific study that Pendulum Therapeutics submitted in response to the action support the claims it has been making.  The specific claims the ruling said were supported on the Pendu...